Table 4 Number of patients and biomarkers of endothelial dysfunction by sex, race, diabetes and medications used
| Â | Number | VCAM-1 (pg/ml) | ICAM-1 (pg/ml) | ELAM-1 (pg/ml) |
|---|---|---|---|---|
Sex | Â | Â | Â | Â |
Female | 64 | 750 (391–2073) | 356 (135–993) | 58 (12–144) |
Male | 10 | 698 (463–1814) | 480 (235–805) | 60 (38–149) |
Race | Â | Â | Â | Â |
Caucasian | 68 | 750 (391–2073) | 366 (135–993) | 61 (12–149) |
Asian | 6 | 572 (463–971) | 352 (235–699) | 49 (35–82) |
Diabetes | Â | Â | Â | Â |
Yes | 5 | 674 (554–1338) | 376 (235–455) | 55 (52–129) |
No | 69 | 749 (391–2073) | 365 (135–993) | 59 (12–149) |
COX-2 inhibitor use | Â | Â | Â | Â |
Yes | 20 | 689 (475–2073) | 371 (145–749) | 79 (25–129) |
No | 54 | 750 (391–2001) | 363 (135–993) | 55 (12–149) |
Traditional NSAID use | Â | Â | Â | Â |
Yes | 19 | 766 (493–2001) | 366 (135–993) | 68 (16–149) |
No | 55 | 703 (391–2073) | 365 (145–761) | 55 (12–129) |
Aspirin use | Â | Â | Â | Â |
Yes | 6 | 719 (463–2073) | 346 (219–595) | 40 (23–94) |
No | 68 | 747 (391–2001) | 366 (135–993) | 62 (12–149) |
Oestrogen use | Â | Â | Â | Â |
Yes | 24 | 673 (445–2001) | 311 (181–993) | 53 (12–83) |
No | 50 | 786 (391–2073) | 389 (135–805) | 64 (20–149) |
DMARD use | Â | Â | Â | Â |
Yes | 56 | 726 (391–2073) | 368 (145–805) | 56 (12–149) |
No | 18 | 816 (567–2001) | 358 (135–993) | 64 (34–115) |
Prednisone use | Â | Â | Â | Â |
Yes | 11 | 930 (391–2073) | 455 (181–761) | 94 (23–129) |
No | 63 | 724 (445–2001) | 361 (135–993) | 55 (12–149) |
Antihypertensive agent use | Â | Â | Â | Â |
Yes | 23 | 744 (569–2073) | 414 (219–805) | 66 (16–149) |
No | 51 | 758 (391–2001) | 350 (135–993) | 54 (12–137) |